.jpg)
Project：ADC2122
Indication：CRC & BC, treated by TOP-1iADCs
Target：Her2
Approach：Pertuzumab ADC, FIC, NK combination
Project：ADC2204
Indication：Bladder, breast,lung
Target：Nectin-4
Approach：Co-development
Project：ADC2154
Indication：Solid Tumors
Target：5T4
Approach：Newco First-to-market
Project：ADC2441
Indication：Solid tumors
Target：5T4/Trop2
Approach：NewcoBsADC. dualpayload
Project：ADC2192
Indication：NSCLC
Target：Trop2
Approach：ADC, dual payload
Project：ADC2313
Indication：Solid Tumors
Target：cMet/EGFR
Approach：BsADC, dual payload
Project：ADC2317
Indication：CRC
Target：CDH17
Approach：FIC/BIC
Project：ADC2431
Indication：Pan-cancer
Target：Undisclosed
Approach：FIC
Project：ADC2616
Indication：SCLC,BsADC，dualneuroendocrine
Target：Undisclosed
Approach：BsADC, dual payload
Project：ADC2631
Indication：Solid tumors
Target：Undisclosed
Approach：FIC
ACR122 is a FIC pertuzumab ADC in clinical development, which has a pertuzumab/Perjeta biosimilar antibody, a microtubule inhibitor DUO-5 (a Dolastatin 10 derivative), a proteolytically cleavable valine-citruline dipeptide linker, and a DAR of 2. Pertuzumab is different from trastuzumab in that it binds to HER2 domain II, instead of IV for trastuzumab, and inhibits not only homodimerization of HER2 itself, but also HER2 and EGFR, HER2 and HER3, HER2 and HER4 heterodimerization. ACR122 has completed Phase Ia dose escalation, demonstrating a favorable safety, efficacy and stability profile, with no interstitial lung disease observed to date. A Phase Ib study is forthcoming, evaluating ACR122 in combination with NK cells in colorectal cancer, as well as a monotherapy study in colorectal cancer patients pretreated with pertuzumab. Given its distinct microtubule-inhibitory mechanism versus TOP1 inhibitors such as irinotecan, ACR122 may retain activity in colorectal cancer patients previously treated with TOP1 inhibitors.
ADC2204 is a next-generation antibody-drug conjugate (ADC) targeting Nectin-4, developed in collaboration with Shandong Lunan Pharmaceutical Group. Nectin-4 is a cell adhesion molecule highly expressed in multiple solid tumors, including urothelial carcinoma, breast cancer, and lung cancer, and has become a well-validated target in the ADC field. Employing a differentiated linker-payload strategy designed to enhance tumor-selective release and reduce off-target toxicity, the product has demonstrated dose-dependent potent antitumor activity across multiple tumor xenograft models in preclinical developability assessments. Its safety profile was significantly superior to that of the approved same-target ADC PADCEV® (enfortumab vedotin), suggesting a broader therapeutic window. The product has received IND authorizations from both NMPA and FDA, enabling clinical development in both China and the US.
ACR246 is a clinical-stage 5T4 ADC employing a TOP1 inhibitor payload, with best-in-class and first-to-market potential. 5T4 is highly expressed across multiple solid tumors and cancer stem cells and is closely associated with tumor invasion, metastasis, and drug resistance. ACR246 combines precise tumor targeting, a novel TOP1 inhibitor payload, controlled release and bystander killing to enhance efficacy in heterogeneous tumors.
In early 2026, Adcoris entered into an exclusive global strategic collaboration with K2 Therapeutics, under which Adcoris will receive an upfront cash payment, equity consideration, up to US$730 million in development and sales milestones, and tiered royalties of up to a double-digit percentage on global sales.
Enrollment in the CN Phase I trial has been completed, with a favorable safety profile and encouraging antitumor activity observed, and the recommended Phase II dose (RP2D) established. A CN Phase IIa study and a Phase Ib study in combination with a PD-1 inhibitor in gastric cancer are planned in China, followed by a global multicenter Phase Ib monotherapy study expected to begin in the first quarter of 2027.
ADC2192 is a Trop2 targeting dual drug ADC developed based on MuSCTM platform, which consists of two payloads with different MOA to promote synergic effects. It is being evaluated preclinically with a marketed and/or more advanced in development candidate head-to-head comparison. Initial data has already shown excellent synergic effects and superior efficacy compared to the reference in several CDX models.
For more information，please contact us at BD@adcoris.com.cn